Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971333 | 0.81 | LMNA (0.32) | TSHRLMNAMAPK1SCN4ASCN5A | |
| Hydrochloric Acid SCHEMBL5442303 | 0.76 | — | — | |
| SCHEMBL4753850 | 0.74 | TSHR (0.50) | TSHRLMNAMAPK1SCN4ASCN5A | |
| SCHEMBL4973582 | 0.74 | — | — | |
| SCHEMBL5005100 | 0.70 | — | — | |
| SCHEMBL1650756 | 0.64 | LMNA (0.37) | TSHRLMNAMAPK1SCN4ASCN5A | |
| SCHEMBL5739502 | 0.64 | ATM (0.30) | — | |
| SCHEMBL2120774 | 0.63 | P2RX4 (0.39) | TSHRLMNAMAPK1SCN4ASCN5A | |
| SCHEMBL15570101 | 0.62 | NOTUM (0.36) | TSHRLMNAMAPK1SCN4ASCN5A | |
| SCHEMBL305168 | 0.62 | HDAC3 (0.43) | TSHRLMNAMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3304080-A1 | METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-11 | — | — | EP | claimed |
| WO-2017005711-A1 | PHOSPHOROUS-AND SULFUR-SUBSTITUTED BENZODIAZEPINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-12 | — | — | WO | claimed |
| WO-2016189042-A1 | METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | WO | claimed |
| EP-3010909-A1 | SUBSTITUTED PHENYL-2,3-BENZODIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-27 | — | — | EP | claimed |
| EP-2958909-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | claimed |
| WO-2015121226-A1 | 6-SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | claimed |
| WO-2015121227-A1 | 6,9-DISUBSTITUTED 1-PHENYL-3H-2,3-BENZODIAZEPINES AND THEIR USE AS BROMODOMAIN INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | claimed |
| EP-2885286-A1 | 2,3-BENZODIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-06-24 | — | — | EP | claimed |
| WO-2014202578-A1 | SUBSTITUTED PHENYL-2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-24 | — | — | WO | claimed |
| WO-2014128067-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | claimed |
| WO-2014026997-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-20 | — | — | WO | claimed |
| US-20180164317-A1 | METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-14 | — | — | US | disclosed |
| EP-3304080-A1 | METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017005711-A1 | PHOSPHOROUS-AND SULFUR-SUBSTITUTED BENZODIAZEPINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-12 | — | — | WO | disclosed |
| WO-2016189042-A1 | METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | WO | disclosed |
| WO-2015121226-A1 | 6-SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| EP-2885286-A1 | 2,3-BENZODIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014202578-A1 | SUBSTITUTED PHENYL-2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014128067-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014026997-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180164317-A1 | METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS | MITF, TFAM, POLRMT | TSHR 757/4885LMNA 3244/4885MAPK1 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.